Showing 2581-2590 of 5646 results for "".
- Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of Lytenavahttps://modernod.com/news/outlook-therapeutics-completes-patient-enrollment-for-norse-2-study-of-lytenava/2477982/Outlook Therapeutics announced the completion of patient enrollment in its NORSE 2 clinical trial for ONS-5010/Lytenava (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. “We are extremely grateful to the patients and medical staff
- Ocutrx Says It Will Deliver World’s First 5G AR/XR Medical Specific Platform in 2021https://modernod.com/news/ocutrx-says-it-will-deliver-worlds-first-5g-ar-xr-medical-specific-platform-in-2021/2477980/Ocutrx Vision Technologies announced plans to deliver the first AR headsets specific for medical applications providing connectivity from AT&T and using 5G products from Qualcomm Technologies. Ocutrx is building its AR/XR medical device, the Oculenz headset, for patient use; and a seco
- Apple Was Already Developing Handwashing Sensing Before COVID-19 Hithttps://modernod.com/news/apple-was-already-developing-handwashing-sensing-before-covid-19-hit/2477981/When Apple vice president of technology Kevin Lynch announced at WWDC last week that Apple Watch would add an automatic handwashing-detection feature in its next update, many people naturally assumed the feature was prompted by the COVID-19 pandemic – a public health emergency that has strongly u
- Hydroxychloroquine Found to Significantly Cut Death Rates in New COVID-19 Studyhttps://modernod.com/news/hydroxychloroquine-found-to-significantly-cut-death-rates-in-new-covid-19-study/2477971/According to a large-scale retrospective analysis published in the International Journal of Infectious Diseases, hydroxychloroquine was associated with a significant decrease in death rate in patients hospitalized with COVID-19, and without heart-related side-effects. Marcus Zervos, division head
- Moderna Reiterates July Start for Phase 3 COVID-19 Vaccine Trial Following Report of Delayhttps://modernod.com/news/moderna-reiterates-july-start-for-phase-3-covid-19-vaccine-trial-following-report-of-delay/2477967/Shares in Moderna fell as much as 9.4% on Thursday after a report indicated that the company’s late-stage trial for potential COVID-19 vaccine mRNA-1273 will be delayed. According to the report in STAT News citing unnamed investigators involved in running the trial, which was slated to begin July
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorderhttps://modernod.com/news/massachusetts-eye-and-ear-enters-licensing-agreement-with-biogen-to-develop-treatment-for-inherited-retinal-disorder/2477961/Massachusetts Eye and Ear is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa. Inhe
- SparingVision Receives European Orphan Designation for its Drug Candidate SPVN06 Dedicated to Inherited Retinal Dystrophieshttps://modernod.com/news/sparingvision-receives-european-orphan-designation-for-its-drug-candidate-spvn06-dedicated-to-inherited-retinal-dystrophies/2477959/SparingVision announced the decision of the European Commission to grant Orphan Drug Designation for SPVN06 for the treatment of inherited retinal dystrophies. The decision is based on a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).
- Hospitals in New COVID-19 Hot Spots Face Delicate Balancing Act With Elective Surgerieshttps://modernod.com/news/hospitals-in-new-covid-19-hot-spots-face-delicate-balancing-act-with-elective-surgeries/2477955/Some hospital systems located in states that are seeing huge spikes of COVID-19 are continuing to perform elective procedures and developing strategies to avoid a total shutdown, according to a FierceHealthcare
- Santen and NTC Announce Positive Outcome of European Decentralised Procedure (DCP) for Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-and-ntc-announce-positive-outcome-of-for-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2477944/Santen EMEA and NTC, have announced the completion and positive outcome of the European Decentralised Procedure (DCP) for a fixed dose combination of levofloxacin and dexamethasone (Ducressa), offering reduced exposure to antibiotics following cataract surgery.1 Levofloxacin is a broa
- Registration Now Open for Neuro-Optometric Rehabilitation Association Online Conferencehttps://modernod.com/news/registration-now-open-for-neuro-optometric-rehabilitation-association-online-conference/2477928/Registration is now open for the Neuro-Optometric Rehabilitation Association, International (NORA) online conference at www.nora2020.com. The conference will be available live online on Saturday, September 12–Sunday, September 13. All presentations will be av